Bayer Interim Report Q2 2016

“We are pleased that Animal Health sales for the first half of 2016 rose by 6.4% (Fx & portfolio adj.) to EUR834 million. And we are very encouraged with the continued growth of Seresto. Within the first half of 2016, Seresto grew 62% (Fx adj.) to EUR121 million, surpassing its 2015 full year sales achievement,” said Dirk Ehle, Head of Animal Health. “We continue to further our commitment to innovations that contribute to animal health. In May, we executed a global license agreement with TransferTech Sherbrooke in Quebec, Canada, to advance a novel vaccine candidate that was discovered at Université de Sherbrooke, to help protect dairy cattle from Staphylococcus aureus mastitis. And in the same month, we joined forces with BioNTech to develop innovative mRNA vaccines and therapeutics for animal health applications. We look forward to being able to bring more breakthrough products to help address unmet veterinary needs,” Ehle added.